PR94232

SEOUL, South Korea, Jan. 27, 2022 /PRNewswire=KYODO JBN/ --

-An innovative  Wireless Brainwave Scanning & Mapping device Attracts the Media

and Public Attention from Visitors Around the World  

iMediSync, A biotech startup company from Seoul, South Korea, successfully

debuted at CES 2022 to introduce the new trend of digital healthcare under

their motto – Overcome Mental Pandemic in just 10 Min.

At the event, the company presented iSyncWave, a dry EEG helmet that provides

EEG, HRV measurement equipped with the world first age/gender matching Norm DB

built with over 1,800 healthy brainwaves to provide a comparative analysis

report to the subject.

iSyncWave's main features follow below:

-Nineteen channel electrodes with gear that automatically adjust to the 10/20

system

-Age/gender matching EEG and HRV analysis & assessment report in 10 minutes

-PBM - Near InfraRed LED Therapy

During CES 2022, the company caught the attention of the media and visitors

from all over the globe. Each day, more than three hundred visitors came to the

booth including audiences such as doctors, clinicians, entrepreneurs,

YouTubers, influencers, and interested parties.

On the first day of CES, nearly one hundred visitors were able to participate

in their real-time brainwave measurement and to learn more about the brain and

QEEG.

A promising start for the iMediSync continued its momentum with interest from

all kinds of audiences including the CTA VIP tours.

The CEO Dr. Seung Wan Kang comments, "The purpose of this showcase is to

introduce our technology and our goal that we will provide life-changing mental

healthcare experience in the field of neuro-mental illness biomarker with our

patent EEG/HRV technology, we strive to provide an optimized individual mental

healthcare service in the post-Covid-19 era."

Aside from iMediSync's innovation and technology, the booth received numerous

visits from key personnel to discuss collaboration in digital healthcare fields

and to expand to the global market of brain science and neurology.

iMediSync, expecting the IPO this year has established close cooperation with

various research facilities and medical organization around the world is

continuing discussion with major pharmaceutical companies for cooperation.

With the Korean FDA approval for their product and the software, iMediSync

expects the FDA and CE approval in the first half of 2022 to expand further on

their biomarkers along with developing a next-level product to declare

themselves as a trend leader in the field.

Source: iMediSync

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=413778

   Caption: Attendees waiting in the line to experience the iSyncWave at CES 2022

   Link: http://asianetnews.net/view-attachment?attach-id=413780

   Caption: Attendee experiencing the new iSyncWave at the iMediSync booth